James E Flynn Insider Trading $LRMR Larimar Therapeutics, Inc.
Get free email notifications about insider trading for James E Flynn.
- Your email is safe with us.
- The service is free and you can unsubscribe at any time.
General | Insider Transactions | Monthly Overview
Get the latest insider transactions of James E Flynn. James E Flynn is 10% Owner in CAS MEDICAL SYSTEMS INC ($CAMY.OB) and 10% Owner in AxoGen, Inc. ($LECT) and 10% Owner in PAR PHARMACEUTICAL COMPANIES, INC. ($PRX) and 10% Owner in Fibrocell Science, Inc. ($FCSC) and 10% Owner in STREAMLINE HEALTH SOLUTIONS INC. ($LANV) and 10% Owner in ANTARES PHARMA, INC. ($ATRS) and 10% Owner in VIA Pharmaceuticals, Inc. ($CAQ) and 10% Owner in DUSA PHARMACEUTICALS INC ($DUSA) and 10% Owner in HI TECH PHARMACAL CO INC ($HITK) and 10% Owner in AVADEL PHARMACEUTICALS PLC ($AVDL) and 10% Owner in INSPIRE PHARMACEUTICALS INC ($ISPH) and 10% Owner in RIGEL PHARMACEUTICALS INC ($RIGL) and 10% Owner in ARENA PHARMACEUTICALS INC ($ARNA) and 10% Owner in ISTA PHARMACEUTICALS INC ($ISTA) and 10% Owner in MEDICINES CO /DE ($MDCO) and 10% Owner in THIRD WAVE TECHNOLOGIES INC /WI ($TWTI) and 10% Owner in DYNAVAX TECHNOLOGIES CORP ($DVAX) and 10% Owner in Cyclacel Pharmaceuticals, Inc. ($CYCC) and Director in Talon Therapeutics, Inc. ($EMLR) and 10% Owner in LUMOS PHARMA, INC. ($NLNK) and 10% Owner in NITROMED INC ($NTMD) and 10% Owner in XENOPORT INC ($XNPT) and 10% Owner in EMAGEON INC ($EMAG) and 10% Owner in CATALYST BIOSCIENCES, INC. ($CBIO) and 10% Owner in ALIMERA SCIENCES INC ($ALIM) and 10% Owner in NeuroMetrix, Inc. ($NURO) and 10% Owner in NxStage Medical, Inc. ($NXTM) and 10% Owner in aTYR PHARMA INC ($LIFE) and 10% Owner in Vanda Pharmaceuticals Inc. ($VNDA) and 10% Owner in XERIS PHARMACEUTICALS INC ($XERS) and Director in PROTEON THERAPEUTICS INC ($PRTO) and 10% Owner in eHealth, Inc. ($EHTH) and 10% Owner in ZAFGEN, INC. ($ZFGN) and 10% Owner in NeurogesX Inc ($NGSX) and 10% Owner in Invuity, Inc. ($IVTY) and 10% Owner in Dicerna Pharmaceuticals Inc ($DRNA) and 10% Owner in CONSTELLATION PHARMACEUTICALS INC ($CNST) and 10% Owner in TriVascular Technologies, Inc. ($TRIV) and 10% Owner in Auspex Pharmaceuticals, Inc. ($ASPX) and 10% Owner in Neos Therapeutics, Inc. ($NEOS) and 10% Owner in Schrodinger, Inc. ($SDGR) and 10% Owner in CytomX Therapeutics, Inc. ($CTMX) and Director in Acutus Medical, Inc. ($AFIB) and 10% Owner in Annexon, Inc. ($ANNX) and 10% Owner in Aclaris Therapeutics, Inc. ($ACRS) and 10% Owner in Syros Pharmaceuticals, Inc. ($SYRS) and 10% Owner in Mallinckrodt plc ($MNK) and 10% Owner in Loxo Oncology, Inc. ($LOXO) and 10% Owner in Adverum Biotechnologies, Inc. ($AAVL) and 10% Owner in REGENXBIO Inc. ($RGNX) and 10% Owner in Recro Pharma, Inc. ($REPH) and 10% Owner in Nivalis Therapeutics, Inc. ($NVLS) and Director in Nivalis Therapeutics, Inc. ($NVLS) and 10% Owner in Audentes Therapeutics, Inc. ($BOLD) and 10% Owner in SteadyMed Ltd. ($STDY) and 10% Owner in ShockWave Medical, Inc. ($SWAV) and 10% Owner in RHYTHM PHARMACEUTICALS, INC. ($RYTM) and 10% Owner in Editas Medicine, Inc. ($EDIT) and Director in AveXis, Inc. ($AVXS) and 10% Owner in ARVINAS INC. ($ARVN) and 10% Owner in Homology Medicines, Inc. ($FIXX) and Director in Homology Medicines, Inc. ($FIXX) and Director in Oncorus, Inc. ($ONCR) and 10% Owner in Revolution Medicines, Inc. ($RVMD) and 10% Owner in Black Diamond Therapeutics, Inc. ($BDTX) and 10% Owner in Frequency Therapeutics, Inc. ($FREQ) and Director in DFB Healthcare Acquisitions Corp. ($DFBH) and 10% Owner in Generation Bio Co. ($GBIO) and 10% Owner in Kiniksa Pharmaceuticals, Ltd. ($KNSA) and 10% Owner in Mirum Pharmaceuticals, Inc. ($MIRM) and 10% Owner in Cabaletta Bio, Inc. ($CABA) and 10% Owner in Werewolf Therapeutics, Inc. ($HOWL) and 10% Owner in Nkarta, Inc. ($NKTX) and 10% Owner in Edgewise Therapeutics, Inc. ($EWTX) and Director in DFP HEALTHCARE ACQUISITIONS CORP. ($DFPH) and Director in Deerfield Healthcare Technology Acquisitions Corp. ($DFHT) and 10% Owner in Terns Pharmaceuticals, Inc. ($TERN).
James E Flynn in Larimar Therapeutics, Inc.
Trading Symbol: LRMRIndustry: PHARMACEUTICAL PREPARATIONS [2834]
Position of James E Flynn: 10% Owner
Holdings: 247,413 shares
Current Value: $1,014,393
Latest Transaction: Aug 01 2016
$LRMR Market Capitalization: $109.05M
$LRMR Previous Close: $4.10
Last 4 weeks trend: HOLD
Last 3 months trend: HOLD
Latest Insider Trading Transactions of James E Flynn in Larimar Therapeutics, Inc.
1 Week | 2 Weeks | 1 Month | 3 Months | 6 Months | 1 Year | 2 Years | |
---|---|---|---|---|---|---|---|
No. of Purchases | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
Value of Purchases ($) | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
No. of Sales | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
Value of Sales ($) | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
Sentiment: All, ACRS, AFIB, DFBH, ADVM, ALIM, ALPN, ANNX, ATRS, ARNA, ARVN, LIFE, BOLD, ASPX, AVDL, AVXS, LECT, BDTX, CABA, CAMY.OB, CBIO, CNST, CYCC, CTMX, DFHTW, DFPHU, DRNA, DUSA, DVAX, EWTX, EDIT, EHTH, EMAG, FCSC, FREQ, GBIO, HITK, FIXX, ISPH, IVTY, ISTA, KNSA, LRMR, LOXO, NLNK, MNK, MDCO, MIRM, NEOS, NGSX, NURO, NTMD, NKTX, NXTM, ONCR, PRX, TARA, REPH, RGNX, RVMD, RYTM, RIGL, SDGR, SWAV, STDY, LANV, SYRS, EMLR, TERN, TWTI, TRIV, VNDA, CAQ, HOWL, XNPT, XERS
Page: 1
Date | Ticker | Company | Owner | Relationship | Transaction | Code | Cost ($) | Shares | Transaction Value ($) | Total Shares | % Holdings |
---|---|---|---|---|---|---|---|---|---|---|---|
Aug 01 2016 | ZFGN | ZAFGEN, INC. | Flynn James E | 10% Owner | Sell | S | 3.31 | 901,430 | 2,985,356 | 1,151,802 | 2.1 M to 1.2 M (-43.90 %) |
Aug 01 2016 | ZFGN | ZAFGEN, INC. | Flynn James E | 10% Owner | Sell | S | 3.31 | 246,439 | 816,157 | 314,889 | 561.3 K to 314.9 K (-43.90 %) |
Aug 01 2016 | ZFGN | ZAFGEN, INC. | Flynn James E | 10% Owner | Sell | S | 3.31 | 193,630 | 641,264 | 247,413 | 441 K to 247.4 K (-43.90 %) |
Feb 17 2016 | ZFGN | ZAFGEN, INC. | Flynn James E | 10% Owner | Buy | P | 6.25 | 13,872 | 86,653 | 2,053,232 | 2 M to 2.1 M (+0.68 %) |
Feb 17 2016 | ZFGN | ZAFGEN, INC. | Flynn James E | 10% Owner | Buy | P | 6.25 | 28,377 | 177,260 | 561,328 | 533 K to 561.3 K (+5.32 %) |
Feb 17 2016 | ZFGN | ZAFGEN, INC. | Flynn James E | 10% Owner | Buy | P | 6.25 | 22,296 | 139,274 | 441,043 | 418.7 K to 441 K (+5.32 %) |
Feb 11 2016 | ZFGN | ZAFGEN, INC. | Flynn James E | 10% Owner | Buy | P | 6.19 | 504 | 3,119 | 2,039,360 | 2 M to 2 M (+0.02 %) |
Feb 11 2016 | ZFGN | ZAFGEN, INC. | Flynn James E | 10% Owner | Buy | P | 6.19 | 1,030 | 6,374 | 532,951 | 531.9 K to 533 K (+0.19 %) |
Feb 11 2016 | ZFGN | ZAFGEN, INC. | Flynn James E | 10% Owner | Buy | P | 6.19 | 810 | 5,013 | 418,747 | 417.9 K to 418.7 K (+0.19 %) |
Feb 11 2016 | ZFGN | ZAFGEN, INC. | Flynn James E | 10% Owner | Buy | P | 6.23 | 32,501 | 202,556 | 2,038,856 | 2 M to 2 M (+1.62 %) |
Feb 11 2016 | ZFGN | ZAFGEN, INC. | Flynn James E | 10% Owner | Buy | P | 6.23 | 66,486 | 414,361 | 531,921 | 465.4 K to 531.9 K (+14.28 %) |
Feb 11 2016 | ZFGN | ZAFGEN, INC. | Flynn James E | 10% Owner | Buy | P | 6.23 | 52,239 | 325,569 | 417,937 | 365.7 K to 417.9 K (+14.28 %) |
Feb 11 2016 | ZFGN | ZAFGEN, INC. | Flynn James E | 10% Owner | Buy | P | 5.73 | 24,484 | 140,271 | 2,006,355 | 2 M to 2 M (+1.24 %) |
Feb 11 2016 | ZFGN | ZAFGEN, INC. | Flynn James E | 10% Owner | Buy | P | 5.73 | 50,086 | 286,948 | 465,435 | 415.3 K to 465.4 K (+12.06 %) |
Feb 11 2016 | ZFGN | ZAFGEN, INC. | Flynn James E | 10% Owner | Buy | P | 5.73 | 39,353 | 225,457 | 365,698 | 326.3 K to 365.7 K (+12.06 %) |
Page: 1